DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas

DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas

Latent Epstein-Barr virus (EBV) infection is associated with several types of cancer. Several clinical studies have targeted EBV antigens as immune therapeutic targets with limited efficacy of EBV malignancies, suggesting that additional targets might be important. BamHI-A rightward frame 1 (BARF1)...

Full description

Bibliographic Details
Main Authors: Xizhou Zhu, Alfredo Perales-Puchalt, Krzysztof Wojtak, Ziyang Xu, Kun Yun, Pratik S. Bhojnagarwala, Devivasha Bordoloi, Daniel H. Park, Kevin Liaw, Mamadou A. Bah, Paul M. Lieberman, Ebony N. Gary, Ami Patel, David B. Weiner
Format: Article
Language:English
Published: Elsevier 2022-03-01
Series:Molecular Therapy: Oncolytics
Subjects:
BARF1
EBV
EBV-associated cancers
DNA immunotherapy
cytotoxic T lymphocytes, viral oncogene
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770521001893

Internet

http://www.sciencedirect.com/science/article/pii/S2372770521001893

Similar Items